Skip to main content

One-Third of Patients Persist on Antiobesity Medications at Six Months

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 7, 2024.

By Lori Solomon HealthDay Reporter

FRIDAY, Jan. 5, 2024 -- Later-stage persistence with antiobesity medication (AOM) varies based on the drug and six-month weight loss, according to a study published online Dec. 6 in Obesity.

Hamlet Gasoyan, Ph.D., M.P.H., from the Cleveland Clinic, and colleagues examined the percentage of patients with an initial AOM fill who were persistent with AOM at three, six, and 12 months and characterized factors associated with persistence at 12 months. The analysis included 1,911 patients (median baseline body mass index of 38 kg/m2) with an initial AOM prescription filled between 2015 and 2022 at a large health system.

The researchers found that 44 percent of patients were persistent with AOM at three months, 33 percent at six months, and 19 percent at 12 months. The highest one-year persistence of AOM was in patients receiving semaglutide (40 percent; adjusted odds ratio [aOR], 4.26; 95 percent confidence interval [CI], 3.04 to 6.05) compared with phentermine-topiramate, while naltrexone-bupropion (aOR, 0.68; 95 percent CI, 0.46 to 1.00) trended toward lower odds compared with phentermine-topiramate. Among patients with six-month persistence, each 1 percent increase in weight loss at six months was associated with 6 percent increased odds of persistence at year 1 (aOR, 1.06; 95 percent CI, 1.03 to 1.09).

"Our findings indicate that although later-stage persistence with AOM remains low, patients receiving more effective AOMs and those experiencing greater medium-term weight loss have higher odds of later-stage persistence," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted January 2024

Read this next

Small Differences in Weight Change With First-Line Antidepressants

MONDAY, July 1, 2024 -- For eight first-line antidepressants, small differences are seen in mean weight change, with the least weight gain with bupropion, according to a study...

Bariatric Surgery Tied to Lower Risk of MACE, Death in Obesity, Sleep Apnea

FRIDAY, June 28, 2024 -- Metabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with nonsurgical management among...

Exercise + GLP-1 RA Effective for Weight Loss While Preserving BMD

THURSDAY, June 27, 2024 -- For adults with obesity, without diabetes, combining exercise with the glucagon-like peptide-1 receptor agonist (GLP-1 RA), liraglutide, is effective...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.